Lost WWI submarine captured in never-before-seen images off the California coast
A World War I submarine wreck off the coast of Southern California has been captured for the first time in new video and images made possible using advanced deep-sea imaging technology.
The sunken U.S. Navy vessel now resting on the San Diego seafloor is known as the USS F-1. F-class submarines were based in the Pacific, serving at Hawaii and off California. The F-1 was lost at sea following an accidental collision on December 17, 1917, resulting in the death of 19 crew members. While others were rescued, the submarine sank in just 10 seconds. It was found again nearly 60 years later, according to the Submarine Force Library and Museum Association.
The high-definition images of the over a century-old submarine were taken in February and March, when researchers at the Massachusetts-based Woods Hole Oceanographic Institution used a human-occupied vehicle called 'Alvin' and the autonomous underwater vehicle named 'Sentry' to travel down 1,300 feet below the surface of the Pacific waters.
'Once we identified the wreck and determined it was safe to dive, we were able to capture never-before-seen perspectives of the sub,' WHOI's Bruce Strickrott, manager of the Alvin Group at WHOI and the sub's senior pilot, said in a statement. 'As a U.S. Navy veteran, it was a profound honor to visit the wreck of the F-1 with our ONR and NHHC colleagues aboard Alvin.'
The mission also included team members from the Navy, the Naval History and Heritage Command, and the National Science Foundation.
The National Science Foundation completed surveys of the submarine using video cameras, imaging systems on Alvin, as well as sonar systems on Sentry and the research vessel Atlantis. They also examined a Navy torpedo bomber training aircraft that crashed near the same location in 1950.
The sonar on Atlantic and Sentry was used to produce maps of the wreck and seafloor, while Alvin's cameras captured images of the wreck that was stitched into models capable of measuring the sub and the marine life it now supports. Researchers were also able to reconstruct the F-1 and create a three-dimensional model.
The dives were part of a previously planned training and engineering mission to give pilots-in-training time to hone their skills and to allow for the development of new technology.
'While these depths were well within the dive capability for Alvin and Sentry, they were technical dives requiring specialized expertise and equipment,' Anna Michel, the co-lead of the expedition, said. 'We were careful and methodical in surveying these historical sites so that we could share these stunning images, while also maintaining the reverence these sites deserve.'
Following the dives, they held a remembrance ceremony on Atlantic, ringing a bell for each of the service members lost at sea.
'History and archaeology are all about people and we felt it was important to read their names aloud," said Naval History and Heritage Command Underwater Archaeologist Brad Krueger. It was his first in-person dive on a historical wreck site. "The Navy has a solemn responsibility to ensure the legacies of its lost Sailors are remembered.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
What to know about UK warning on weight loss drugs' effect on birth control
Regulators in the United Kingdom issued guidance on Thursday, warning that weight loss and diabetes medications may weaken the effectiveness of birth control and may be harmful for pregnant women. The Medicines and Healthcare products Regulatory Agency (MHRA) said women taking tirzepatide, sold under the brand name Mounjaro, may need to use another form of contraception. This is because Mounjaro, a medication licensed to treat diabetes and for weight loss management in the U.K. in conjunction with diet and exercise, may reduce the effectiveness of oral contraceptives in those who are overweight. MORE: Compound versions of GLP-1 drugs for weight loss halted by FDA The MHRA advised women taking Mounjaro who are overweight and are using an oral form of contraception to also use a non-oral form of contraception, such as a birth control implant, an intrauterine device or condoms. The agency said using a backup form of birth control is especially important for the four weeks after starting Mounjaro and after any increase in dosage. It also advised taking a second form of birth control for up to two months after taking this class of medications before trying to become pregnant, and recommended against use while pregnant, breastfeeding or trying to become pregnant. Similarly, the U.S. Food and Drug Administration recommended women on Mounjaro and using oral contraceptives switch to a non-oral form of birth control and use "a barrier method" four weeks after starting use or after a dose increase. Obstetrics experts told ABC News there have been anecdotal reports of women becoming pregnant while taking tirzepatide -- which falls under a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1s -- even though they were on a birth control pill. There are two reasons this may be happening, experts said. Dr. Elizabeth Langen, an associate professor and maternal-fetal medicine specialist at University of Michigan Health, told ABC News that pregnancy may become more likely in some women after they lose weight. Additionally, GLP-1s may affect digestion and an oral form of contraception may not be absorbed as effectively, she said. "Some of these medications change how we digest food and/or medications," Langen said. "It slows that process down, and so we might not have the same blood levels of the hormones that we're expecting to if we're taking an old contraceptive drug, because the weight loss or diabetes medication is impacting our digestion." MORE: Weight-loss meds may give people more control over drinking, study shows Dr. Christina Boots, a reproductive endocrinology and infertility specialist at Northwestern Medicine in Chicago, said she's not sure if the recommendation for a backup form of contraception came from data seen during phase I or phase II clinical trials or if researchers saw more incidental pregnancies in those early studies. She said sexually active patients who are on weight loss medications should speak to their doctor if they're concerned about getting pregnant. The MHRA also warned that medicines like Mounjaro included Ozempic, Wegovy, Saxenda and Victoza should not be taken during pregnancy, while trying to get pregnant or during breastfeeding. The agency said this is because there is a lack of safety data on whether taking the medicine could cause harm to a fetus. Boots said there are no formal guidelines on the use of GLP-1s in pregnancy. Studies done on rodents suggest there could be birth defects and problems with metabolic function, but no large studies have been conducted on humans. "With these newer weight loss medications, the challenge is basically that we, unfortunately, don't have a lot of data on how they're going to impact fetal development and how they might impact a mom's health during her pregnancy," Langen said She went on, "There are other means of controlling diabetes [and] weight loss. We tend to favor those because we know that they're safe for both the mom and the fetus during a pregnancy."
Yahoo
15 hours ago
- Yahoo
Regeneron makes obesity push; Atai, Alto ink brain drug deals
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Regeneron and Bluebird bio, as well as updates from Atai Life Sciences, Alto Neuroscience and UniQure that you may have missed. Regeneron Pharmaceuticals on Monday disclosed Phase 2 study results that it claimed suggest the addition of one or two of its experimental medicines to Novo Nordisk's Wegovy might help people with obesity preserve muscle mass. Leerink Partners analyst David Risinger, however, described the results in a research note as "mixed," highlighting how the addition of Regeneron's drug resulted in either numerically lower weight loss with "comparable tolerability" or "greater weight loss with worse tolerability." The effects on muscle function, which haven't yet been disclosed, will be "critical,' Risinger added. Draft guidance published by the Food and Drug Administration has indicated muscle-protecting medicines "need to demonstrate functional benefits" to succeed. — Ben Fidler Regeneron also expanded its portfolio of weight-loss medicines, announcing on Monday a deal for most worldwide rights to a drug developed by Hansoh Pharmaceuticals Group that's currently in late-stage testing in obesity in China. Regeneron paid Hansoh $80 million upfront for the drug, which, like Eli Lilly's Zepbound targets the gut hormones GLP-1 and GIP. It could add nearly $2 billion in additional payouts. In testing, the drug has demonstrated a "potentially similar profile" to Zepbound, Regeneron said. — Ben Fidler Carlyle Group and SK Capital on Monday closed a deal to acquire and take private gene therapy developer Bluebird bio. The two private equity firms said they've provided 'significant primary capital' to support and scale Bluebird's gene therapies for rare blood and brain diseases, and that the company will now prioritize building up its manufacturing capabilities and strengthening relationships with insurers. Bluebird's stock, which will no longer trade on the Nasdaq, last closed at around $5 per share. — Ben Fidler Psychedelics developer Atai Life Sciences is absorbing the rest of a U.K.-based biotechnology company through an all-share transaction announced Monday. Atai last year took a nearly 36% stake in Beckley Psytech, providing it access to an experimental version of the mind-altering compound mebufotenin. Now, the two developers are combining in a deal that values Beckley at $390 million and is expected to close in the back half of this year. Beckley's investors other than Atai will be issued around 105 million new shares as consideration, representing about 31% of the combined company. Additionally, the investment firms Ferring Ventures and Adage Capital Partners are making a concurrent $30 million private placement. Atai said the new entity will have enough cash to keep it running through 'multiple' readouts of important mid-stage clinical trials. — Jacob Bell Alto Neuroscience has, for just under $2 million, acquired a portfolio of dopamine-boosting drugs in development for depression. The deal with Chase Therapeutics, disclosed Tuesday, hands Alto a fixed-dose combination of pramipexole, which is already used to treat Parkinson's disease, and ondansetron, the active ingredient in the nausea medication Zofran. Now code-named ALTO-207, this combination recently succeeded in a mid-stage study of patients with major depressive disorder. Alto plans to start by mid-2026 a Phase 2b trial designed to potentially enable an approval application. The trial would focus on treatment-resistant depression and report high-level data sometime in 2027. — Jacob Bell UniQure, the Belgium-based gene therapy developer, said it has reached an agreement with the FDA on 'several key components' of an approval application for its closely watched treatment for Huntington's disease. Those components include the manufacturing process for the treatment, named AMT-130, as well as updated statistical analysis plans that UniQure expects to submit before the end of June. Looking ahead, the company intends to have another pre-filing meeting with the FDA late this year and then formally submit its application for priority review sometime between January and March of 2026. Analysts at TD Cowen have estimated that peak annual sales of AMT-130 could reach or surpass around $1 billion. — Jacob Bell Recommended Reading Sanofi reaches consumer health deal; Supernus antidepressant fails study Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Yahoo
Bug-eyed telescope ready to find Earth-smashing asteroids
It's only a matter of time before a catastrophically sized asteroid barrels towards Earth again. Until very recently in human history, there was no way of knowing if one was hurtling towards us, much less do anything to alter its path. Now, international space agencies and disaster preparedness experts have powerful tools to keep watch over the skies—and the newest aide just opened its bug-inspired compound 'eye.' According to the European Space Agency, the Flyeye-1 telescope recently completed its 'first light' test at the Italian Space Agency's Space Geodesy Center, located about 160 miles east of Naples. Soon, it and as many as three other similar installations around the world will work in tandem to provide comprehensive, automated surveys of space every night to scan for cosmic threats. 'The earlier we spot potentially hazardous asteroids, the more time we have to assess them and, if necessary, prepare a response,' explains Richard Moissl, Head of ESA's Planetary Defence Office. 'ESA's Flyeye telescopes will be an early-warning system, and their discoveries will be shared with the global planetary defence community.' Similar to an insect's vision (hence its name), Flyeye captures incoming light through its 3.3-foot-wide primary mirror. That light is divided into 16 independent channels, all equipped with their own secondary lens and detector cameras designed to flag extremely faint objects. Flyeye's automated observation schedule is designed to factor in variables such as lunar brightness along with other survey telescopes like NASA's ATLAS, the Zwicky Transient Facility, and the forthcoming Vera Rubin Telescope. So what happens if Flyeye spies a suspicious space rock out there in deep space? The plan is for experts at ESA's Near-Earth Object Coordination Center (NEOCC) to review and verify any potential concerns. If the situation warrants further investigation, the NEOCC will then forward their report to the Minor Planet Center, a global hub for asteroid data. Subsequent research will lead to international contingency planning, which could involve any number of solutions, such as smacking the asteroid off course with a targeted spacecraft launch. Before that can happen, Flyeye needed to demonstrate its up to the task. For its first light test, Flyeye focused on multiple known asteroids, including 2025 KQ. Astronomers discovered the space rock only two days earlier, offering direct proof that the telescope is already capable of rapid follow-up observations. 'These images of the sky above the ancient stone hills of Matera, Italy, are more than just a test—they are proof that Flyeye is ready to begin its mission,' ESA said in its announcement. Flyeye-1 is now on its way for installation on Monte Mulfara in Sicily. If all goes according to plan, the telescope's first sibling will be up and running sometime in 2028.
